Is neratinib (neratinib) available in domestic hospitals?

Neratinib (Neratinib) is an oral targeted therapy primarily used to treat HER2 (human epidermal growth factor receptor 2)-positive breast cancer. HER2Positive breast cancer is a common subtype of breast cancer, characterized by overexpression of HER2 receptors on tumor cells, which promotes abnormal proliferation of cancer cells and tumor progression. Neratinib (neratinib) was developed to block the growth and spread of cancer cells by inhibiting the HER2 receptor and its related signaling pathways.

Neratinib (neratinib) is now available in the domestic market and has been successfully included in the medical insurance system. Patients can purchase it directly in the country, and the price is about 7,000 to 8,000 yuan. However, for specific prices and detailed policies on medical insurance reimbursement, please consult your local hospital or pharmacy for accurate information.

In addition, if you are looking for a more economical option, Bangladeshi generic drugs are a good choice. The price is only about more than 3,000 yuan, which is nearly half the price of domestic drugs, and the ingredients of the drugs are basically the same as the domestic versions.

As a targeted therapy drug,neratinib (neratinib) has multiple mechanisms of action. It is a tyrosine kinase inhibitor that can bind to the HER2 receptor and inhibit its activation, thereby blocking the growth signaling of cancer cells. In addition, neratinib (neratinib) can also affect other related signaling pathways, such as PI3K/AKT and MAPK, etc., thus comprehensively interfering with the growth and proliferation of cancer cells and promoting their apoptosis (programmed cell death).

Clinical trials have demonstrated the effectiveness of neratinib (neratinib) in the treatment of early-stage and metastatic HER2-positive breast cancer. In early-stage breast cancer, the ExteNET clinical trial showed that after surgical resection and other standard treatments, patients who received neratinib (neratinib) had a 33% lower risk of cancer recurrence than those who received a placebo. In metastatic breast cancer, neratinib (neratinib) is often used as a subsequent treatment option, which can help control tumor progression and prolong patient survival.